Assessing readiness

Learning Objectives

By the end of this module, the trainee will be able to:

• Recognize when readiness depends on a medical safeguard, distinguish care that is separable from the administration (coordinate it, ideally through the client's own treating team) from care that is inseparable (a stop, not a caution), and route the legal question to counsel (Criteria 2 and 41).
• Explain the receptor pharmacology of classic psychedelics, distinguish it from MDMA, ketamine, and ibogaine, and describe how predictive processing models inform questions about screening without proving a universal response.
• Describe the entropic brain and relaxed beliefs (REBUS) accounts as models, and distinguish their predictions from established human clinical findings.
• Use amplification as a clinical heuristic, distinguish preclinical plasticity findings from human evidence, and explain why supportive context is reasonable without asserting selective consolidation of a person’s emotional state.
• Distinguish absolute psychiatric contraindications from relative cautions and from conditions that are frequently an indication for the work rather than a reason to exclude.
• Identify the cardiovascular and metabolic factors that determine physiological readiness, and state the mechanism behind the serotonin 2B valvular concern.
• Assess psychological readiness as a set of measurable capacities, trait absorption, distress tolerance, emotion regulation, and reflective function, rather than a global impression.
• Assess social readiness as a property of the environment a person returns to, not only of the person.
• Identify reported associations between acute experience, psychological flexibility, and outcomes, distinguish them from validated individual prediction, and use assessment findings to set preparation and support goals.
• Apply a three-domain plus timing framework to reach a defensible proceed, defer, or refer decision, and articulate the reasoning in writing.

Key Terms

Readiness. The assessment of psychological stability, social support, physiological safety, consent capacity, and timing for a proposed intervention. It identifies current concerns and preparation needs; it cannot guarantee that an individual will benefit or avoid harm.

5-HT2A receptor. The serotonin 2A receptor, densely expressed on layer 5 cortical pyramidal neurons. Agonism at this receptor is the primary initiating action of the classic serotonergic psychedelics (Nichols, 2016).

Prior (predictive processing). A high-level expectation or belief the brain uses to organize and predict experience. Under predictive-processing accounts, perception and cognition are driven by the brain's models of the world, and psychedelics are modeled to relax the precision and the confidence weighting of these priors (Carhart-Harris & Friston, 2019).

Entropy (entropic-brain model). In this model, a measure of the disorder or uncertainty of large-scale brain activity. The entropic-brain hypothesis proposes that psychedelics raise the entropy of cortical dynamics, moving the brain toward a less constrained, more flexible state (Carhart-Harris et al., 2014).

Amplification. Amplification can be a useful clinical heuristic for understanding how existing emotions, concerns, memories, interpersonal dynamics, and environmental cues may become unusually salient during a psychedelic experience. It should not be interpreted as a literal rule that all psychedelic content existed beforehand in latent form. Psychedelic states can also produce novel associations, altered interpretations, unusual perceptual content, false insights, and high confidence beliefs that require careful evaluation after the acute state. McGovern et al. (2024) propose a model of false insights and beliefs; it does not establish how often these occur.

Neuroplasticity window. A proposed period of altered susceptibility to learning or change after exposure. Ly et al. (2018) demonstrated structural and functional changes in cellular and animal models, and Shao et al. (2021) found persistent dendritic spine growth in mouse frontal cortex. These findings do not establish a defined human window or which emotional states would be consolidated within it.

Trait absorption. A stable disposition toward deep attentional involvement in sensory and imaginative experience. It is one individual-difference variable associated with the intensity of the acute psychedelic response and is relevant to reading how a person is likely to meet the state.

Distress tolerance. The capacity to withstand aversive internal states without acting to escape them prematurely. It is a central resilience marker for work that predictably produces periods of acute difficulty.

Reflective function. The capacity to understand one's own and others' behavior in terms of underlying mental states. It supports a person's ability to make meaning of an intense experience rather than being overwhelmed by it.

Absolute contraindication. A condition under which the intervention should not proceed at all in the setting under consideration, because the risk of serious harm is unacceptable.

Relative contraindication. A condition that raises risk and requires additional evaluation, mitigation, or a higher level of care, without automatically excluding the person.

Sympathomimetic effect. A physiological effect resembling activation of the sympathetic nervous system, here the transient rise in heart rate and blood pressure produced by classic psychedelics (Johnson, Richards, & Griffiths, 2008).

Set and setting. The extra-pharmacological determinants of a psychedelic response: set, the person's mindset, expectation, and preparation, and setting, the physical, social, and cultural environment. The evidence that these shape outcome is among the more robust findings in the field (Hartogsohn, 2016, 2017).

Why readiness screening exists: amplification as a clinical heuristic

Screening is the first real judgment a facilitator makes, and every function downstream inherits it. To understand why it carries the weight it does, we start with what the medicine does to the brain. The classic serotonergic psychedelics, psilocybin among them, act as agonists or partial agonists at the serotonin 2A receptor, which sits densely on the layer 5 pyramidal neurons of the cortex (Nichols, 2016). Those neurons carry much of the machinery that holds a person's high-level model of themselves and their world in place.

The leading mechanistic account of what follows is the relaxed beliefs under psychedelics model, or REBUS (Carhart-Harris & Friston, 2019). It builds on an earlier proposal, the entropic-brain hypothesis, which held that psychedelics raise the entropy of large-scale cortical activity and move the brain into a less constrained regime (Carhart-Harris et al., 2014). Under the REBUS account, 2A agonism relaxes the precision of high-level priors, the settled expectations the brain uses to predict, rationalize, and stabilize experience. When those priors loosen, the constraints that ordinarily keep a person's inner world fixed start to give way, and material which is normally held down can surface and reorganize. Both of these are worth stating as models rather than closed facts, because human evidence is still developing and the imaging findings are actively debated, but together they are the most coherent framework currently available, and they have direct consequences for screening.

Amplification can be a useful clinical heuristic for understanding how existing emotions, concerns, memories, interpersonal dynamics, and environmental cues may become unusually salient during a psychedelic experience. It should not be interpreted as a literal rule that all psychedelic content existed beforehand in latent form. Psychedelic states can also produce novel associations, altered interpretations, unusual perceptual content, false insights, and high confidence beliefs that require careful evaluation after the acute state. REBUS and predictive processing offer hypotheses about altered belief updating; receptor agonism does not prove that experiences only reveal preexisting content. Screening therefore examines vulnerabilities, strengths, expectations, and context, while integration allows unusual memories or interpretations to be considered without assuming their factual truth (Carhart-Harris & Friston, 2019; McGovern et al., 2024).

Neuroplasticity and the state a person brings into the session

Psychedelics can alter cortical dynamics acutely, and experiments also show changes that persist after exposure. Ly et al. (2018) demonstrated structural and functional plasticity primarily in cellular and animal models, including changes in neurites, synapses, and dendritic spines. Shao et al. (2021) observed rapid and persistent dendritic spine growth after psilocybin in mouse frontal cortex. These findings provide biological precedents for studying durable change. They do not demonstrate that a distressed human emotional state will be preferentially encoded, or establish the timing of a human intervention window.

Psychedelic exposure can produce neuroplastic changes in preclinical models, and human research increasingly supports a period of altered learning, cognition, and psychological flexibility surrounding psychedelic treatment. The extent to which particular environmental, interpersonal, or emotional states become preferentially consolidated during this period in humans remains unresolved. Clinical attention to context and post experience support remains reasonable without treating selective consolidation as an established neurobiological mechanism. Readiness includes the weeks around the proposed experience because sleep, ongoing symptoms, relationships, practical demands, and access to care can affect recovery and participation. Providing support and reassessing deterioration do not require proof that a particular state is being biologically consolidated. Neural Attunement proposes testable relationships among post acute state, input, physiology, and later function; those relationships remain hypotheses requiring human validation (Ly et al., 2018; Shao et al., 2021).

What readiness assessment can and cannot establish

A screening framework needs a clear purpose: identify current hazards, assess informed participation, and plan preparation and support. Psychological flexibility, distress tolerance, social support, therapeutic alliance, expectations, surrender, and other baseline factors may be clinically relevant to that work. Associations with psychedelic outcomes have been reported, but the evidence does not currently support using any one of these constructs as a validated individual predictor of therapeutic benefit or harm. A proceed decision means the assessed conditions and program requirements are met; it does not predict a successful therapeutic response (Viljoen et al., 2026).

Acute experience quality has been associated with later outcomes in some studies. Roseman, Nutt, and Carhart-Harris (2018) reported associations in a small open label treatment resistant depression study; this does not establish that a more intense or “complete” experience causes improvement. A 2026 systematic review of 54 studies found acute intensity, particularly mystical type experience, the most frequently reported predictor of response, but the association was inconsistent across diagnoses and time points and stronger methods were needed (Viljoen et al., 2026). Davis, Barrett, and Griffiths (2020) used a retrospective cross sectional survey and statistical mediation analysis to relate reported flexibility changes to reported depression and anxiety changes. That analysis supports a candidate pathway, not proof of causal mediation or a prospectively validated readiness measure.

Distress tolerance, emotion regulation, and reflective function help structure questions about how a person currently handles difficulty, requests help, and reflects on experience. The assessment can guide additional preparation, clinical referral, and support without ranking these capacities as proven drivers of benefit. Their relevance to planning is distinct from an ability to forecast an individual outcome. Therapeutic response prediction remains an active research area, and readiness screening should not be replaced with a target for mystical experience or intensity (Viljoen et al., 2026).

Psychological readiness

Risk related to bipolar spectrum disorders, mania, and psychosis must be evaluated in relation to the specific intervention. Different psychedelic and psychedelic adjacent compounds act through different pharmacological systems and cannot be assigned a single serotonergic mechanism of psychiatric risk. Current mood state, history of mania or psychosis, medication regimen, sleep disruption, substance use, family history, and compound specific evidence should inform screening and clinical decision making. Active mania or psychosis warrants deferral and psychiatric evaluation. Personal and family histories may lead to elevated screening or exclusion under a specific protocol; a research exclusion is not proof of a universal contraindication. Classic psychedelic trials have often excluded these histories (Johnson, Richards, & Griffiths, 2008; Davis et al., 2021). Ketamine has been investigated for bipolar depression, including small controlled and open label studies alongside mood stabilizing treatment, so its assessment cannot be derived from a blanket serotonergic explanation. This evidence does not remove the need for psychiatric supervision or establish safety during active mania (Bahji et al., 2021).

The dimensional point matters more than the diagnostic label. A diagnosis in the chart is less informative than the person's current stability. A person with well-managed anxiety who is stable in ongoing therapy may be well prepared. A person in acute crisis is not, whatever their diagnosis. Note also that depression, anxiety, and post-traumatic stress are frequently the reason a person seeks this work rather than a reason to turn them away, since these are the conditions in which supervised psychedelic and entactogen therapy has shown benefit (Davis et al., 2021; Mitchell et al., 2021).

Reading for resilience means asking about specific capacities rather than forming a global impression. Emotion regulation concerns how a person responds to strong feeling. Distress tolerance concerns remaining with discomfort without immediately acting to escape it; it is a useful assessment domain, not an established single most important predictor of psychedelic benefit. Reflective function concerns understanding behavior in terms of mental states and considering more than one interpretation. Trait absorption, a disposition toward deep involvement in imaginative or sensory experience, has been associated with aspects of acute response, but cannot reliably predict an individual’s response or safety. Ask for concrete examples, how support is used, and what happens when coping strategies fail. These findings inform preparation and referral alongside current symptoms and safety needs (Viljoen et al., 2026).

Social readiness

Readiness depends in part on the world a person returns to after a session. Set and setting describe the extra-pharmacological factors that shape the response to the drug, and the evidence that context is a genuine determinant of outcome is among the more robust findings in the field (Hartogsohn, 2016). The history of the concept shows that drug effects are, in a real sense, constructed by the environment and expectations surrounding them rather than read off the molecule alone (Hartogsohn, 2017). Setting extends past the room and past the day of the session into the relationships, the housing, and the obligations that will either hold a person or pull them under during the vulnerable weeks of integration. Preclinical plasticity findings provide a rationale for studying this period, but they do not establish a defined plasticity window in humans.

An abusive or unsafe return environment creates practical safety concerns that need to be addressed with the person and appropriate services. It does not establish that the environment will biologically overwrite the experience. Supportive relationships may help with recovery, while their absence can complicate follow up. Screening asks about safe housing, accessible clinical and integration support, and obligations such as childcare, work, and caregiving. The decision should name the actual unmet need and the available plan, rather than infer a neural outcome from the environment alone.

Physiological readiness

Cardiovascular screening remains central. Classic psychedelics can transiently increase heart rate and blood pressure, so uncontrolled hypertension and significant cardiac disease require medical review (Johnson, Richards, & Griffiths, 2008). Chronic activation of cardiac 5 HT2B receptors is an established mechanism associated with drug induced valvular disease for several non psychedelic medications. Some psychedelics also bind to or activate 5 HT2B receptors, creating a theoretical concern particularly with repeated or sustained exposure. Clinically significant valvular disease from one or several widely spaced therapeutic psychedelic exposures has not been demonstrated, but available human evidence is insufficient to quantify long term risk. Chronic or frequent exposure warrants separate consideration from intermittent therapeutic dosing. The 5 HT2B concern is distinct from acute blood pressure effects or ibogaine related QT prolongation. A receptor binding finding or mechanistic comparison cannot quantify an individual’s long term valve risk (McIntyre, 2023; Rouaud, Calder, & Hasler, 2024).

Beyond the heart, screening attends to seizure disorders, hepatic and renal function, and pregnancy. Metabolism matters here: psilocybin is a prodrug, rapidly dephosphorylated to its active form psilocin, which is then cleared through hepatic pathways, so significant hepatic impairment can alter exposure (Nichols, 2016). Operational screening tools, resting blood pressure, an electrocardiogram where cardiac history or risk factors warrant one, and a structured medical history, translate these concerns into practice. The specific numeric thresholds a program uses to trigger further evaluation or medical clearance are policy decisions that should be set with qualified medical oversight rather than improvised by a facilitator, and this module does not assign a citation to any single threshold because no single universal standard exists in the peer-reviewed literature.

Timing and life circumstances

Recent bereavement or major life disruption should prompt careful assessment of current functioning, psychological stability, suicidality, support, informed consent capacity, treatment goals, and the individual’s ability to tolerate an intensive altered state. Bereavement itself should not be presented as an established pharmacological or psychiatric contraindication. A decision to defer should identify current concerns such as acute suicidality, severe functional instability, uncontrolled symptoms, inadequate support, intoxication, or impaired consent. A recent loss or divorce alone does not supply that conclusion, and preclinical plasticity findings do not prove that upheaval will be consolidated. The PARTING study is an open label pilot trial protocol investigating prolonged cancer related grief, not evidence that psychedelic treatment is established for acute bereavement. Discuss goals and uncertainties and coordinate clinical input where needed (Beesley et al., 2025).

The screening posture and scope of practice

Two commitments hold this criterion together. The first is humility about scope. No facilitator and no program can hold everything, and some people need stabilization inside conventional care before this work is appropriate at all. Saying not yet is a clinical act, and a facilitator should be as skilled at it as at saying yes. The second is that the first trust is built or lost here. How screening is conducted, whether it feels mechanical and rushed or thorough and unhurried, tells a person what kind of program they have entered, and even a person who is turned away can leave the process feeling seen when the tone and the reasoning are honest. This criterion pairs with Criterion 2, which takes the coexisting medical, psychiatric, and pharmacological conditions this screen surfaces and routes them to the right professional.

When readiness depends on a medical safeguard: the threshold that ends screening

One screening finding deserves separate treatment, because it changes the nature of the decision rather than merely weighting it. Screening ordinarily sorts people into proceed, defer and prepare, or refer, and the middle option carries the implicit promise that a caution can be worked on and revisited. Some findings break that promise. Where a client's safe participation would depend on a medical intervention, and the substance they are seeking is Schedule I, the intervention that would make them safe cannot simply be arranged the way an ordinary medical referral can. The reasoning is developed in Criterion 2, and its legal structure is taught in Criterion 41; what matters at the screening stage is the conclusion. A facilitator screening a client whose safety would require, for instance, continuous cardiac monitoring with intravenous access through the session is not looking at a caution to be managed with a phone call. They are looking at a requirement that no one may lawfully meet under current US law.

The discipline this imposes at screening is a distinction rather than a blanket refusal. Ask whether the medical care the client would need is separable from the administration of the substance. Care that is separable stands on its own clinical footing and does not require a clinician to handle or give the substance: a cardiac evaluation and clearance beforehand, a prescriber managing the client's own medication, a treating physician managing their blood pressure, a clinician contracted to be present and respond to a medical emergency as they would at any gathering. That care can frequently be arranged lawfully, and the best route is usually the client's own treating team, whose involvement is both lawful and clinically superior to anything a facilitator could improvise. Screening that surfaces a need for separable care is doing exactly what screening is for, and the correct action is to coordinate it. Care that is inseparable from the administration is different. Where the safeguard functions only if it is delivered during the session and as an integral part of the administration, arranging it means arranging for a clinician to participate in an unlawful act, and no logistics solve that. A finding of that kind is a stop rather than a caution: the client is screened out of the unlawful setting and routed toward a lawful one, which in practice means an authorized clinical trial, a jurisdiction where a clinician may lawfully provide the care, or a different path altogether. Whether any particular arrangement is defensible is a legal question with real consequences for the clinician involved, and it belongs with an attorney rather than with a facilitator's judgment. What screening owes the client is the honesty to recognize the finding and to name it, rather than to treat as a logistics problem something that is in truth a gate.

Clinical and Decision Tools

Tool 1. Three-domain readiness indicators

Use this as a structured read across all three domains plus timing. It orients judgment; it does not replace it. A single Stop indicator halts the process pending evaluation. A pattern of Caution indicators calls for preparation before proceeding.

Tool 2. Psychological resilience read

Where Tool 1 identifies current safety concerns, this tool structures inquiry into coping, reflection, and support needs. It is a guide to conversation and narrative documentation, not a scored instrument or a validated prediction of who can “carry” or “metabolize” an experience. Record how each finding changes preparation, referral, or support.

Tool 3. Psychiatric conditions reference

Contraindication status reflects the setting under consideration. A condition that is absolute for an unsupported retreat may be manageable in a medically supervised clinical setting. When in doubt, refer for psychiatric evaluation before proceeding. Shaded rows mark stop-and-refer findings.

Tool 4. Physiological red flags and recommended action

Tool 5. Readiness-to-preparation map

A defer decision is only useful if it names what preparation must accomplish. This tool translates the most common caution findings into concrete preparation goals and a marker of what completion looks like, so that deferral becomes a plan rather than a delay.

Tool 6. Decision framework

Integrate the three domains and timing into one of three defensible outcomes. Document the outcome and its reasoning.

Proceed. All domains meet Proceed indicators, no Stop indicators present. Move to intake and preparation.

Defer and prepare. The person is fundamentally appropriate but a domain needs strengthening first, more support, better timing, a controlled medical condition. Use Tool 5 to set concrete conditions and a path back.

Refer out. A Stop indicator or an out-of-scope need is present. Route to the appropriate professional, warmly and with clear reasoning. See Criterion 2 and Core Function XII.

Worked Examples: Completed Readiness Evaluations

The following are models of the reasoning and documentation this criterion should produce. Details are fictional.

Worked Example 1: A defer-and-prepare decision

Client: R.M., 42, seeking psilocybin-assisted work for long-standing treatment-resistant depression. Referred by a treating therapist.

Psychological: Diagnosis of major depressive disorder, recurrent. No personal or family history of psychotic or bipolar disorder. In weekly therapy for two years with a stable alliance. Reports good distress tolerance and a prior history of using difficult experiences reflectively. No current suicidal ideation; passive ideation eighteen months ago, since resolved. Read: Proceed indicators present; depression is an indication, not an exclusion. On the resilience read, emotion regulation and reflective function are strong; prior integration is documented.

Social: Lives with a supportive spouse who is informed and on board. Stable housing and employment. Treating therapist willing to provide integration support during recovery and follow up. Read: Proceed.

Physiological: No cardiac history; resting blood pressure within normal range on two readings. Taking an SSRI under psychiatric care. Current SSRI treatment does not automatically require discontinuation before psilocybin. Read: Caution pending review of the specific medication, treatment indication, duration of use, withdrawal history, clinical stability, and setting. The clinical team may consider continuation or a change; the facilitator does not select the medication plan (Becker et al., 2022; Goodwin et al., 2023; Erritzoe et al., 2024).

Timing: No acute stressor. Adequate time protected for integration. Read: Proceed.

Decision: Defer and prepare until the prescriber and appropriately qualified psychedelic medicine clinician complete the individualized medication review and document clinical stability. A completed SSRI washout is not the universal marker of readiness. If a change is proposed, withdrawal and recurrence of depression require reassessment; continuing treatment may also be an appropriate clinical plan. Document the reasoning and share it with the treating team with the client’s signed release.

Worked Example 2: A refer-out decision

Client: D.L., 34, self-referred, seeking psilocybin work for what they describe as a spiritual crisis and periods of feeling that thoughts are being placed in their mind.

Psychological: Reports two prior episodes involving disordered thinking and a sense of external control, neither formally evaluated, plus a sibling hospitalized for psychosis. Read: Stop the proposed session and refer for psychiatric evaluation of the current symptoms and relevant history. The concern is this person’s unassessed presentation and the proposed psilocybin exposure; family history alone is not proof of an inevitable adverse reaction. Conservative research exclusions support careful screening but do not measure individual risk (Johnson, Richards, & Griffiths, 2008).

Social and physiological: Not the limiting factors here and not the basis of the decision. A stop indicator in one domain halts the process regardless of strength elsewhere.

Decision: Refer out. Route to psychiatric evaluation, framed as care rather than rejection: the experiences described warrant assessment in their own right, and that assessment has to come first. Document the reasoning. Do not schedule. This is a case where saying not yet, and possibly not at all in this setting, is the competent clinical act.

Case Vignettes

Work each vignette across all three domains plus timing, reach a Proceed, Defer, or Refer decision, and write one paragraph defending it. The fillable response sheets are in the companion worksheet PDF.

Vignette A

A 29-year-old arrives motivated and psychologically curious, with good insight and no psychiatric red flags. They live alone, recently moved to a new city, and have no local support network. They want to do deep trauma work.

Guided questions: Which domain needs attention? What support and follow up would be adequate for this individual and setting? Is there a current safety concern requiring deferral, or can support be arranged? How do you distinguish a reasonable support plan from an unproven claim that isolation will consolidate distress through neuroplasticity?

Vignette B

A 51-year-old is physically active, medically confident, and dismissive of the preparation process, describing it as unnecessary hand-holding. They are currently taking a selective serotonin reuptake inhibitor and want to attend an ayahuasca retreat in three weeks.

Guided questions: What is the specific pharmacological hazard in this profile? What has to happen before this person could safely proceed, and who has to be involved? How do you address the dismissiveness toward preparation without losing the alliance?

Vignette C

A 38-year-old is medically healthy, well supported, psychologically stable, and lost a parent to suicide five weeks ago. They feel an urgent pull to do psychedelic work to process the grief.

Guided questions: What do current functioning, sleep, suicidality, support, consent capacity, and treatment goals show? Does recent bereavement alone justify a contraindication? What additional information or clinical consultation is needed? Explain a decision to proceed, defer, or refer from the current assessment, without claiming that grief will be biologically consolidated or that psilocybin is an established acute grief treatment.

Vignette D

A 45-year-old with well-managed generalized anxiety, stable in therapy for three years, presents for psilocybin work. On the resilience read they show strong reflective function but describe a lifelong pattern of avoiding intense emotion and leaving situations the moment discomfort rises. Medically clear, well supported, good timing.

Guided questions: What preparation or support needs does the reported avoidance pattern suggest? What current clinical concerns require review? Explain the limits of distress tolerance as an individual outcome predictor, and distinguish a practical preparation plan from a claim that training guarantees benefit.

Vignette E

A 60-year-old with treatment-resistant depression is a strong psychological and social fit. Medical history includes hypertension, currently uncontrolled on their most recent two readings, and they mention occasional chest tightness on exertion that they have not had evaluated.

Guided questions: Which domain halts this, and why does it halt it regardless of the strong fit elsewhere? What is the sympathomimetic concern in concrete terms? What specific clearance and evaluation do you require, and is the undisclosed chest tightness a defer or a stop?

Role-Play and Practice Scripts

Practice these in pairs, one facilitator and one client, then switch. The goal is to gather what safety requires while communicating that the person is being met rather than examined.

Opening the psychiatric history

“I am going to ask some direct questions about mental health, including things people do not always get asked about. This is how I make sure this is safe for you, and it is not a test you can fail. Have you or anyone in your immediate family ever experienced psychosis, mania, or been diagnosed with schizophrenia or bipolar disorder?”

Reading resilience, not just risk

“Tell me about a time something in your life was genuinely hard to sit with. What did you do, and what did you take from it afterward?” Practice listening for distress tolerance, reflective function, and prior integration rather than steering the person toward a right answer.

Asking about suicidality

“Have you had thoughts of ending your life, recently or in the past? If yes, can you tell me about when, and what things are like for you now?” Practice staying calm and unhurried, and knowing your program’s threshold for pausing the process and referring.

The medication and supplement review

“I need the full list of everything you take, prescription, over the counter, and supplements, including anything you take only occasionally. Some combinations are genuinely dangerous with these medicines, so this part matters.” Practice recognizing SSRI plus ayahuasca and MAOI plus serotonin releasing or reuptake inhibiting agents as serious interaction concerns; other MAOI combinations require compound specific review, and hand off to Criterion 2 for the full review.

Assessing the return environment

“Walk me through the two weeks after a session as they would actually look. Who is around you, where are you living, what obligations are pulling on you?” Practice hearing the setting a person returns to as part of the readiness picture, not an afterthought.

Delivering a not-yet decision

“Based on everything we have discussed, I do not think now is the right time, and I want to tell you exactly why, because it is not a no forever. Here is what I would want to see in place first, and here is how we get there.”

Self-Assessment and Reflection

Knowledge check

1. Name the principal receptor mechanism for classic psychedelic effects and explain why it does not apply unchanged to MDMA, ketamine, and ibogaine. How can a predictive processing model guide questions without proving that all content existed beforehand?
2. State the entropic-brain and REBUS models in one sentence each, and explain why each is described as a model rather than a settled finding.
3. Distinguish demonstrated preclinical plasticity from a proposed human post acute window. Why is attention to context and support reasonable even though selective consolidation of emotional states remains unresolved?
4. Explain how active mania or psychosis differs from a stable personal or family history. Which compound specific evidence and psychiatric consultation are needed, and why is a trial exclusion not itself proof of a universal contraindication?
5. Name the psychological capacities this module foregrounds, describe how to assess them, and distinguish their use in support planning from validated individual prediction.
6. Explain the established 5 HT2B mechanism for several non psychedelic drugs and the theoretical concern for repeated psychedelic exposure. What remains unknown about both frequent dosing and a few widely spaced therapeutic exposures?
7. Give one profile in which a person is medically and psychologically ready but should still be told not yet.

Reflection

1. Recall a time you, or someone you observed, let enthusiasm for an outcome override a safety judgment. What indicator was missed, and what would have caught it?
2. Where is the edge of your own scope of practice? Name one type of client you should refer rather than hold, and identify the professional you would refer to.
3. Consider a person whose return support is limited. What current symptoms, practical risks, and consent or follow up needs change the decision? Explain your reasoning without assuming that preclinical plasticity findings predict the person’s emotional consolidation.

Summary

Criterion 1 assesses psychological, social, physiological, and timing factors before a proposed intervention. Amplification is a useful clinical heuristic for heightened salience of existing concerns; it does not exclude novel associations, false insights, or altered interpretations. REBUS and the entropic brain account remain models. Cellular and animal plasticity findings support investigation of post acute change, while selective consolidation of particular human emotional states and a defined intervention window remain unresolved. Psychiatric screening considers current mood and psychotic symptoms, relevant history, medication, sleep, and the specific compound. Social screening identifies practical support and safety needs. Physiological screening preserves cardiac and medication review, with uncertainty accurately stated for 5 HT2B related valve concerns. Recent grief warrants assessment of functioning, consent, goals, and support rather than automatic exclusion. A psilocybin medication review does not automatically require SSRI discontinuation. The outcome remains a documented proceed, defer, or refer decision within the program’s scope, with coexisting concerns routed through Criterion 2.

References

Carhart-Harris, R. L., & Friston, K. J. (2019). REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics. Pharmacological Reviews, 71(3), 316–344. https://doi.org/10.1124/pr.118.017160

Carhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014). The entropic brain: A theory of conscious states informed by neuroimaging research with psychedelic drugs. Frontiers in Human Neuroscience, 8, 20. https://doi.org/10.3389/fnhum.2014.00020

Davis, A. K., Barrett, F. S., & Griffiths, R. R. (2020). Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. Journal of Contextual Behavioral Science, 15, 39–45. https://doi.org/10.1016/j.jcbs.2019.11.004

Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry, 78(5), 481–489. https://doi.org/10.1001/jamapsychiatry.2020.3285

Hartogsohn, I. (2016). Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology. Journal of Psychopharmacology, 30(12), 1259–1267. https://doi.org/10.1177/0269881116677852

Hartogsohn, I. (2017). Constructing drug effects: A history of set and setting. Drug Science, Policy and Law, 3, Article 2050324516683325. https://doi.org/10.1177/2050324516683325

Johnson, M. W., Richards, W. A., & Griffiths, R. R. (2008). Human hallucinogen research: Guidelines for safety. Journal of Psychopharmacology, 22(6), 603–620. https://doi.org/10.1177/0269881108093587

Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., Duim, W. C., Dennis, M. Y., McAllister, A. K., Ori-McKenney, K. M., Gray, J. A., & Olson, D. E. (2018). Psychedelics promote structural and functional neural plasticity. Cell Reports, 23(11), 3170–3182. https://doi.org/10.1016/j.celrep.2018.05.022

McIntyre, R. S. (2023). Serotonin 5-HT2B receptor agonism and valvular heart disease: Implications for the development of psilocybin and related agents. Expert Opinion on Drug Safety, 22(10), 881–883. https://doi.org/10.1080/14740338.2023.2248883

Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot’alora G., M., Garas, W., Paleos, C., Gorman, I., Nicholas, C., Mithoefer, M., Carlin, S., Poulter, B., Mithoefer, A., Quevedo, S., Wells, G., Klaire, S. S., van der Kolk, B., … Doblin, R. (2021). MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine, 27(6), 1025–1033. https://doi.org/10.1038/s41591-021-01336-3

Nichols, D. E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264–355. https://doi.org/10.1124/pr.115.011478

Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018). Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Frontiers in Pharmacology, 8, 974. https://doi.org/10.3389/fphar.2017.00974

Rouaud, A., Calder, A. E., & Hasler, G. (2024). Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins. Journal of Psychopharmacology, 38(3), 217–224. https://doi.org/10.1177/02698811231225609

Shao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021). Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron, 109(16), 2535–2544.e4. https://doi.org/10.1016/j.neuron.2021.06.008

Becker, A. M., Holze, F., Grandinetti, T., Klaiber, A., Toedtli, V. E., Kolaczynska, K. E., Duthaler, U., Varghese, N., Eckert, A., Grünblatt, E., & Liechti, M. E. (2022). Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects. Clinical Pharmacology & Therapeutics, 111, 886–895. https://doi.org/10.1002/cpt.2487

Goodwin, G. M., Croal, M., Feifel, D., Kelly, J. R., Marwood, L., Mistry, S., O’Keane, V., Knatz Peck, S., Simmons, H., Sisa, C., Stansfield, S. C., Tsai, J., Williams, S., & Malievskaia, E. (2023). Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology, 48, 1492–1499. https://doi.org/10.1038/s41386-023-01648-7

Erritzoe, D., Barba, T., Spriggs, M. J., Rosas, F. E., Nutt, D. J., & Carhart-Harris, R. (2024). Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression. Journal of Psychopharmacology, 38, 458–470. https://doi.org/10.1177/02698811241237870

McGovern, H. T., Grimmer, H. J., Doss, M. K., Hutchinson, B. T., Timmermann, C., Lyon, A., Corlett, P. R., & Laukkonen, R. E. (2024). An Integrated theory of false insights and beliefs under psychedelics. Communications Psychology, 2, 69. https://doi.org/10.1038/s44271-024-00120-6

Beesley, V. L., Kennedy, T. J., MacCallum, F., Ross, M., Harvey, R., Rossell, S. L., Sarris, J., Perkins, D., Neale, R. E., Bennett-Levy, J., Johnson, S., Beebe, H., Roset, N., Strobel, J., & Parker, S. (2025). Psilocybin-Assisted suppoRtive psychoTherapy IN the treatment of prolonged Grief (PARTING) trial: protocol for an open-label pilot trial for cancer-related bereavement. BMJ Open, 15, e095992. https://doi.org/10.1136/bmjopen-2024-095992

Bahji, A., Zarate, C. A., & Vazquez, G. H. (2021). Ketamine for Bipolar Depression: A Systematic Review. International Journal of Neuropsychopharmacology, 24, 535–541. https://doi.org/10.1093/ijnp/pyab023

Malcolm, B., & Thomas, K. (2022). Serotonin toxicity of serotonergic psychedelics. Psychopharmacology, 239, 1881–1891. https://doi.org/10.1007/s00213-021-05876-x

Viljoen, G., Walter, H., Bendau, A., Koslowski, M., & Betzler, F. (2026). Predictors of therapeutic response to psychedelic-assisted therapy: A systematic review. Journal of Psychopharmacology, 40, 703–719. https://doi.org/10.1177/02698811251389581